Anti-Mouse CD134 (Clone OX-86) – Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD134 (Clone OX-86) – Purified in vivo PLATINUM™ Functional Grade
Product No.: C856
Clone OX-86 Target CD134 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names OX-40, TNFRSF4, ACT35 Isotype Rat IgG1 Applications Act , FC , IHC , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Additional Applications Reported In Literature ? FC IHC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone OX-86 reacts with murine CD134 (OX-40, TNFRSF4). Background CD134 functions as an important immune checkpoint, and its depletion in murine mouse models demonstrate that lack of CD134 expression leads to reduced CD4+ and CD8+ T cells1. When CD134 is bound by its corresponding ligand (OX-40L), an optimal T cell response is generated and plays a significant role in determining the amount of memory T-cells remaining after the immune response1. CD134 has also been found to play an important role in carcinogenesis, as treatment with activating in vivo antibodies against CD134 enhanced tumor growth, suggesting that CD134 is an important tumor suppressor, and its absence disrupts the immune response to tumors2,3. Antigen Distribution CD134 is expressed on activated CD4 and CD8 T cells, activated regulatory T cells, B cells, NKT cells, NK cells, and neutrophils. Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone OX-86 is a monoclonal antibody that targets mouse OX40 (CD134), acting as an agonist to stimulate the OX40 pathway. Common in vivo applications of clone OX-86 in mice include:
Commonly Used Antibodies and Proteins with OX-86 in the LiteratureOX-86 is a well-established monoclonal antibody against mouse CD134 (OX40/TNFRSF4), primarily used for studying T cell activation, immune checkpoint modulation, and the dynamics of OX40 signaling in various immunological contexts. In published studies, OX-86 is often used in combination with other antibodies and proteins to provide a comprehensive profile of T cell function, activation status, and immune regulation. Key Antibodies Commonly Used with OX-86
Commonly Used Proteins
Application Context
ConclusionOX-86 is most frequently used in concert with antibodies targeting key cytokines (IFN-γ, IL-2, IL-4, IL-17A), T cell markers (CD4, CD25), and the OX40 ligand (CD252). Fusion proteins (e.g., OX40L-fusion constructs) and Fc receptor proteins are also used to probe the biology of the OX40 signaling axis in functional assays. This multi-parameter approach enables researchers to dissect complex T cell responses in the context of OX40 engagement. Clone OX-86 is a monoclonal antibody targeting murine CD134 (OX-40, TNFRSF4) that has generated significant findings across immunology and cancer research. This antibody acts as an agonist, stimulating OX-40 signaling and has been extensively used to investigate T cell responses and anti-tumor immunity. T Cell Costimulation and Cytokine ProductionOX-86 demonstrates potent costimulatory effects on T cells when combined with TCR/CD3 stimulation. Studies show that OX-86 significantly increases IL-2 and IFN-γ production from both CD4+ and CD8+ T cells in a dose-dependent manner. This costimulatory activity enhances T cell proliferation and cytokine secretion, suggesting that OX-40 signaling amplifies the immune response beyond primary TCR activation alone. Role in T Cell Memory FormationWhen CD134 is bound by its corresponding ligand (OX-40L) or agonistic antibodies like OX-86, an optimal T cell response is generated that plays a significant role in determining the amount of memory T cells remaining after the immune response. In vivo treatment with OX-86 has been shown to strongly enhance the generation of antigen-specific effector T cells and prevent the induction of T cell tolerance. This finding has important implications for vaccine development and immunotherapy strategies. Anti-Tumor ActivityResearch demonstrates that OX-86 can delay tumor growth in vivo. However, the mechanism appears complex—treatment with activating in vivo antibodies against CD134 enhanced tumor growth in some contexts, suggesting that CD134 functions as an important tumor suppressor, and its absence disrupts the immune response to tumors. The anti-tumor effects likely depend on the specific tumor microenvironment and the balance of immune cell populations present. NK Cell EnhancementBeyond T cells, OX-86 engagement enhances natural killer (NK) cell function. Studies show that CD134 engagement on NK cells with an agonistic antibody increased antibody-dependent cellular cytotoxicity (ADCC) capacity and IFNγ secretion. This finding expands the therapeutic potential of OX-40 targeting beyond conventional T cell responses. Isotype-Dependent MechanismsThe biological activity of OX-86 varies significantly based on its isotype. The original rat IgG1 version interacts primarily with FcγRIIb and FcγRIII, giving it a low activatory-to-inhibitory FcγR binding ratio and the capacity for direct agonism through FcγRIIb-mediated crosslinking. In contrast, chimeric versions with mouse IgG2a constant regions interact strongly with all activatory FcγR and likely mediate effects through cellular depletion mechanisms rather than pure agonism. Dosing regimens of clone OX-86 (anti-mouse OX40 mAb) vary by mouse model and experimental aim, commonly ranging from 10 µg to 250 µg per injection, with schedules from a single dose to repeated daily or weekly injections.
Toxicity and reaction risks increase at higher doses and more frequent administrations, including potential anaphylaxis with repetitive dosing. Summary table:
In conclusion, the OX-86 clone dosing regimen is highly context-dependent, with lower doses favored for combination therapies to minimize toxicity, and higher/frequent doses used for robust immune activation or mechanistic endpoints. Reviewing individual study protocols and monitoring for adverse reactions, especially at higher frequencies or doses, is recommended. References & Citations1. Redmond WL, Ruby CE, Weinberg AD. Crit Rev Immunol. 29(3):187-201. 2019
2. Morris A, Vetto JT, Ramstad T, et. al. Breast Cancer Res Treat. 67: 71–80. 2001. 3. Weinberg AD, Rivera MM, Prell R, et. al. J Immunol. 164: 2160–9. 2000. 4. al-Shamkhani A, Birkeland ML, Puklavec M, et. al. Eur J Immunol. Aug;26(8):1695-9. 1996. 5. Higgins LM, McDonald SA, Whittle N, et. al. J Immunol. Jan 1;162(1):486-93. 1999. Technical ProtocolsCertificate of Analysis |
Formats Available
